Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Valerie Meuray"'
Autor:
Gilles Gadea, Nikola Arsic, Kenneth Fernandes, Alexandra Diot, Sébastien M Joruiz, Samer Abdallah, Valerie Meuray, Stéphanie Vinot, Christelle Anguille, Judit Remenyi, Marie P Khoury, Philip R Quinlan, Colin A Purdie, Lee B Jordan, Frances V Fuller-Pace, Marion de Toledo, Maïlys Cren, Alastair M Thompson, Jean-Christophe Bourdon, Pierre Roux
Publikováno v:
eLife, Vol 5 (2016)
TP53 is conventionally thought to prevent cancer formation and progression to metastasis, while mutant TP53 has transforming activities. However, in the clinic, TP53 mutation status does not accurately predict cancer progression. Here we report, base
Externí odkaz:
https://doaj.org/article/f581c63f2c83491e9dc7660202f2310e
Autor:
Sun-Young Lee, Claire Robertson, Alexandra Diot, Valerie Meuray, Jean-Christophe Bourdon, Mina J. Bissell
Publikováno v:
Journal of cell science. 135(21)
Growing evidence indicates that p53 (encoded by TP53) has a crucial role in normal tissue development. The role of the canonical p53 (p53α) and its 12 isoforms in development and homeostasis of healthy tissue remains poorly understood. Here, we demo
Autor:
Frances V. Fuller-Pace, Samer Abdallah, Pierre Roux, Christelle Anguille, Marie P. Khoury, Alexandra Diot, Nikola Arsic, Valerie Meuray, Colin A. Purdie, Philip R. Quinlan, Judit Remenyi, St�phanie Vinot, Marion de Toledo, S�bastien M. Joruiz, Ma�lys Cren, Gilles Gadea, Lee B. Jordan, Kenneth Fernandes, Alastair M. Thompson, Jean-Christophe Bourdon
Publikováno v:
eLife
eLife, eLife Sciences Publication, 2016, 5, 〈10.7554/eLife.14734〉
eLife, Vol 5 (2016)
eLife, eLife Sciences Publication, 2016, 5, pp.e14734. ⟨10.7554/eLife.14734⟩
eLife, 2016, 5, pp.e14734. ⟨10.7554/eLife.14734⟩
eLife, eLife Sciences Publication, 2016, 5, 〈10.7554/eLife.14734〉
eLife, Vol 5 (2016)
eLife, eLife Sciences Publication, 2016, 5, pp.e14734. ⟨10.7554/eLife.14734⟩
eLife, 2016, 5, pp.e14734. ⟨10.7554/eLife.14734⟩
TP53 is conventionally thought to prevent cancer formation and progression to metastasis, while mutant TP53 has transforming activities. However, in the clinic, TP53 mutation status does not accurately predict cancer progression. Here we report, base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd6e5e3665203f26a5977193bbf1fdd8
http://hal.univ-reunion.fr/hal-01703040
http://hal.univ-reunion.fr/hal-01703040
Autor:
Sebastien M. Joruiz, Judit Remenyi, Alexandra Diot, Gilles Gadea, Valerie Meuray, Marie P. Khoury, Christelle Anguille, Stéphanie Vinot, Marion de Toledo, Frances V. Fuller-Pace, Philip R. Quinlan, Colin A. Purdie, Nikola Arsic, Kenneth Fernandes, Samer Abdallah, Alastair M. Thompson, Lee B. Jordan, Jean-Christophe Bourdon, Maïlys Cren, Pierre Roux
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b8de1f78025ccf44c1eb1f433992bc2
https://doi.org/10.7554/elife.14734.022
https://doi.org/10.7554/elife.14734.022
Autor:
Alastair M. Thompson, Valerie Meuray, Hervé Bonnefoi, Richard Iggo, David Cameron, Alexandra Diot, Jean-Christophe Bourdon, Leen Slaets
Publikováno v:
Cancer Research. 76:855-855
Background: Studies of TP53 mutation, protein expression and modifications of the p53 network in breast cancer yield a complexity which has so far hindered substantive clinical progress. The effects of p53 mutation and p53 protein expression in breas